CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 57 enrolled
Drug / intervention
Levodopa+carbidopa +1 moredrug
Likely dose
Levodopa+carbidopa 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02513485
NCT02513485Phase 4Completed
CompareCT.gov

"Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa"; "Inflammation Effects on Corticostriatal Connectivity and Reward: Role of Dopamine"

Emory University·interventional·Posted Jul 31, 2015·Updated Sep 19, 2022

In Brief

A Phase 4 clinical trial evaluating Levodopa+carbidopa and Placebo for Depression. Completed, enrolled 57 participants across 1 site.

Detailed Summary

The purpose of this study is to learn more about the changes that happen in the brain and the body when a person is depressed. This study will determine if the level of inflammation in the body is related to symptoms of depression, how well the person thinks, and how certain brain regions communicate.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 31, 2015
Enrollment StartOct 9, 2015
Primary CompletionFeb 21, 2020
Study CompletionAug 1, 2020
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 10.9 years ago

Interventions

Levodopa+carbidopadrug

Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2.

Placebodrug

A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.